From: Expression of HNF-1β in cervical carcinomas: an immunohistochemical study of 155 cases
HNF-1β | ER | PR | CEA | p16 | p63 | p40 | D2-40 | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
pos | neg | pos | neg | pos | neg | pos | neg | pos | neg | pos | neg | pos | neg | pos | neg | ||
ACA | 42 (75%) | 14 (25%) | 9 (16.1%) | 47 (83.9%) | 5 (8.9%) | 51 (91.1%) | 48 (85.7%) | 8 (14.3%) | 56 (100%) | 0 (0%) | 4 (7.2%) | 52 (92.8%) | 2 (3.6%) | 54 (96.4%) | 0 (0%) | 56 (100%) | |
(56 cases) | 3+ | 27 (48.2%) | 2 (3.6%) | 3 (5.4%) | 31 (55.4%) | 52 (92.9%) | 0 | 0 | |||||||||
2+ | 8 (14.3%) | 1 (1.8%) | 1 (1.8%) | 13 (23.2%) | 2 (3.6%) | 1 (1.8%) | 1 (1.8%) | ||||||||||
1+ | 7 (12.5%) | 6 (10.7%) | 1 (1.8%) | 4 (7.1%) | 2 (3.6%) | 3 (5.4%) | 1 (1.8%) | ||||||||||
SCC | 2 (2.35%) | 83 (97.65)% | 9 (10.6%) | 76 (89.4)% | 1 (1.2%) | 84 (98.8%) | 77 (90.6%) | 8 (9.4%) | 84 (98.8%) | 1 (1.2%) | 85 (100%) | 0 (0%) | 85 (100%) | 0 (0%) | 45 (53.6%) | 39 (46.4%) | |
(85 cases) | 3+ | 1 (1.2%) | 3 (3.5%) | 0 | 13 (15.3%) | 83 (97.6%) | 83 (97.6%) | 83 (97.6%) | 15 (17.9%) | ||||||||
2+ | 1 (1.2%) | 2 (2.4)% | 0 | 15 (17.6%) | 0 | 2 (2.4%) | 2 (2.4%) | 15 (17.9%) | |||||||||
1+ | 0 | 4 (4.7%) | 1 (1.2%) | 49 (57.6%) | 1 (1.2%) | 0 | 0 | 15 (17.9%) | |||||||||
UC | 2 (14.3%) | 12 (85.7%) | 0 (0%) | 14 (100%) | 0 (0%) | 14 (100%) | 8 (57.1%) | 6 (42.9%) | 14 (100%) | 0 (0%) | 7 (50%) | 7 (50%) | 5 (35.7%) | 9 (64.3%) | 1 (7.1%) | 13 (92.9%) | |
(14 cases) | 3+ | 1 (7.1%) | 1 (7.1%) | 13 (92.9%) | 4 (28.6%) | 4 (28.6%) | 0 | ||||||||||
2+ | 0 | 2 (14.3%) | 0 | 1 (7.1%) | 0 | 1 (7.1%) | |||||||||||
1+ | 1 (7.1%) | 5 (35.7%) | 1 (7.1%) | 2 (14.3%) | 1 (7.1%) | 0 |